Eliem Therapeutics Inc. (ELYM)
NASDAQ: ELYM
· Real-Time Price · USD
5.11
-0.05 (-0.97%)
At close: Oct 02, 2024, 10:00 PM
Eliem Therapeutics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -23.02M | -69.18M | -11.73M | -4.71M | -3M | -5.12M | -5M | -6.71M | -23.44M | -9.55M | -8.75M | -13.7M | -13.13M | -10.7M | -9.38M | -8.71M | -6.88M |
Interest Income | n/a | -2.69M | n/a | n/a | 1.34M | 1.35M | 1.26M | 1.11K | 409.00 | n/a | 383K | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Income | -20.78M | -13.67M | -8.89M | -54.89M | -1.7M | -3.64M | -3.97M | -5.22M | -22.29M | -7.76M | -9.68M | -14.6M | -13.2M | -10.54M | -9.62M | -8.72M | -18.6M |
Net Income | -20.78M | -13.67M | -8.89M | -54.89M | -1.7M | -3.64M | -3.97M | -5.22M | -21.14M | -5.97M | -9.68M | -15.49M | -13.28M | -10.54M | -9.62M | -8.72M | -18.6M |
Selling & General & Admin | 5.69M | 8.45M | 5.49M | 3.67M | 1.91M | 2M | 2.13M | 3.03M | 17.72M | 4.63M | 4.49M | 4.93M | 4.87M | 3.82M | 3.39M | 2.91M | 2.22M |
Research & Development | 17.33M | 8.91M | 6.09M | 1.05M | 1.09M | 3.13M | 2.88M | 3.69M | 5.72M | 4.93M | 4.26M | 8.77M | 8.26M | 6.88M | 5.99M | 5.79M | 4.66M |
Other Expenses | n/a | 51.82M | 153K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 85K | 60K | 20K | n/a | n/a |
Operating Expenses | 23.02M | 69.18M | 11.73M | 4.71M | 3M | 5.12M | 5M | 6.71M | 23.44M | 9.55M | 8.75M | 13.7M | 13.13M | 10.7M | 9.38M | 8.71M | 6.88M |
Interest Expense | n/a | -1.15M | n/a | n/a | n/a | 1.15M | n/a | n/a | n/a | n/a | n/a | 1.64M | 229K | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | n/a | 69.18M | 11.73M | 4.71M | 3M | 5.12M | 5M | 6.71M | 23.44M | 9.55M | 8.75M | 13.7M | 13.13M | 10.7M | 9.38M | 8.71M | 6.88M |
Income Tax Expense | n/a | 3.01M | n/a | n/a | n/a | -3.06K | -4.78K | n/a | -1.15M | -1.79M | n/a | 895K | 72K | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 67.46M | 48.16M | 67.01M | 30.35M | 27.64M | 27.7M | 27.07M | 26.84M | 26.49M | 26.37M | 26.34M | 26.3M | 26.24M | 26.23M | 15.59M | 23.46M | 11.66M |
Shares Outstanding (Diluted) | 67.46M | 48.16M | 67.01M | 30.35M | 27.64M | 27.7M | 27.07M | 26.84M | 26.49M | 26.37M | 26.34M | 26.3M | 26.24M | 26.23M | 15.59M | 23.46M | 11.66M |
EPS (Basic) | -0.31 | 0.47 | -0.13 | -1.81 | -0.06 | -0.13 | -0.15 | -0.19 | -0.8 | -0.23 | -0.37 | -0.59 | -0.51 | -0.4 | -0.62 | -0.37 | -1.6 |
EPS (Diluted) | -0.31 | 0.47 | -0.13 | -1.81 | -0.06 | -0.13 | -0.15 | -0.19 | -0.8 | -0.23 | -0.37 | -0.59 | -0.51 | -0.4 | -0.62 | -0.37 | -1.6 |
EBITDA | -23.02M | -17.87M | -11.73M | -56.37M | -3M | -5.12M | -5M | -6.71M | -23.44M | -6.15M | -8.75M | -13.7M | -13.13M | -10.7M | -9.38M | -8.71M | -6.88M |
EBIT | n/a | 64.5M | -11.73M | -56.37M | -3M | -5.12M | -5M | -6.71M | -23.44M | -9.55M | -8.75M | -13.7M | -13.13M | -10.7M | -9.38M | -8.71M | -6.88M |
Depreciation & Amortization | n/a | -6.06M | n/a | n/a | 3M | 3.06M | 4.78M | 5.98M | 7.65M | 9.55M | 8.75M | 13.7M | 13.13M | 10.7M | 9.38M | 8.71M | 6.88M |